GRAIL, Inc. (GRAL)
99.25
-5.59
(-5.33%)
USD |
NASDAQ |
Nov 20, 16:00
102.00
+2.75
(+2.77%)
After-Hours: 20:00
GRAIL Research and Development Expense (TTM) : 183.98M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 183.98M |
| June 30, 2026 | 186.05M |
| March 31, 2026 | 185.25M |
| December 31, 2025 | 188.30M |
| September 30, 2025 | 192.80M |
| June 30, 2025 | 215.17M |
| March 31, 2025 | 262.74M |
| Date | Value |
|---|---|
| December 31, 2024 | 313.30M |
| September 30, 2024 | 348.42M |
| June 30, 2024 | 359.98M |
| March 31, 2024 | 354.50M |
| December 31, 2023 | 338.74M |
| September 30, 2023 | 301.03M |
| June 30, 2023 | 257.25M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Moderna, Inc. | 2.401B |
| Twist Bioscience Corp. | 71.84M |
| Prime Medicine, Inc. | 136.33M |
| Kailera Therapeutics, Inc. | 283.60M |
| Oncolytics Biotech, Inc. | 13.18M |